Kangstem Biotech Co., Ltd. (KOSDAQ:217730)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,030.00
-60.00 (-2.87%)
At close: Feb 6, 2026

Kangstem Biotech Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Cash & Equivalents
1,3165,8564,6817,5429,9697,681
Short-Term Investments
24,50431,50431,00839,01824,8017,000
Trading Asset Securities
--988.8210,0263,16433,543
Cash & Short-Term Investments
25,82137,36036,67856,58537,93348,224
Cash Growth
31.09%1.86%-35.18%49.17%-21.34%28.00%
Accounts Receivable
596.36721.61,5671,225660.58332.51
Other Receivables
582.19411.99651.07326.35213.852.06
Receivables
1,9191,1342,2181,551874.38384.57
Inventory
785.37578.26467.15763.77354.86266.39
Prepaid Expenses
32330.83330.06326.9626.0938.16
Other Current Assets
7,3307,9636,2136,1285,5626,495
Total Current Assets
35,88647,36645,90765,35544,75155,408
Property, Plant & Equipment
18,94429,57231,26534,12634,79434,978
Long-Term Investments
7,5482,9501,8332,19867020,633
Other Intangible Assets
364.98440.121,041991.531,1211,789
Long-Term Accounts Receivable
--0-0-0-00
Other Long-Term Assets
1,384925.66546.68477.681,169835.79
Total Assets
64,12881,25380,592103,14882,505113,644
Accounts Payable
327.94324.27406.56850.37385.4616.81
Accrued Expenses
319.57483.99436.08421.19304.28284.76
Short-Term Debt
3,3302,6162,5662,2642,19812,345
Current Portion of Long-Term Debt
4005,5303,7003,500355.5683.33
Current Portion of Leases
575.44808.9752.43844.37829.4472.54
Current Unearned Revenue
330330334.05235.77300.01522.08
Other Current Liabilities
6,8068,5016,0729,0747,8336,274
Total Current Liabilities
12,08918,59414,26717,19112,20620,599
Long-Term Debt
3,1803,3805,2305,63012,42714,804
Long-Term Leases
124.211,2741,1201,8052,3483,228
Pension & Post-Retirement Benefits
-1,507970.8913.72741.23714.82
Other Long-Term Liabilities
1,2766,3756,3016,3236,1445,579
Total Liabilities
16,66931,13027,89031,86233,86644,924
Common Stock
28,02727,96918,96918,96912,41810,425
Additional Paid-In Capital
174,869174,895163,374163,374131,311134,808
Retained Earnings
-162,508-159,354-137,201-117,054-95,670-77,232
Comprehensive Income & Other
7,0704,4694,1942,7513,2901,100
Total Common Equity
47,45947,97849,33668,03951,35069,101
Minority Interest
--3,494-2,110-2,070-2,981-2,001
Shareholders' Equity
47,45950,12352,70271,28648,63968,719
Total Liabilities & Equity
64,12881,25380,592103,14882,505113,644
Total Debt
7,61013,60913,36914,04418,15930,933
Net Cash (Debt)
18,21123,75123,30942,54219,77517,291
Net Cash Growth
164.19%1.90%-45.21%115.13%14.37%-14.67%
Net Cash Per Share
336.41584.98614.401527.64886.87829.71
Filing Date Shares Outstanding
56.0555.9437.9437.9424.8420.85
Total Common Shares Outstanding
56.0555.9437.9437.9424.8420.85
Working Capital
23,79728,77231,64048,16532,54434,809
Book Value Per Share
846.66857.701300.441793.432067.503314.26
Tangible Book Value
47,09447,53848,29567,04850,22967,311
Tangible Book Value Per Share
840.15849.831273.001767.302022.353228.44
Land
3,9278,2497,9847,9847,7981,243
Buildings
9,24110,92010,59610,59610,2112,762
Machinery
414.67595.05590.8533.4539.11522.21
Construction In Progress
548.74310.2223.5250.96-25,964
Source: S&P Global Market Intelligence. Standard template. Financial Sources.